Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
DREPIBAC
1 other identifier
observational
350
1 country
31
Brief Summary
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of these infections over time. New pneumococcal conjugate vaccines have recently become available, and updated data are needed to better understand which bacteria are currently responsible for invasive infections in this population. The aim of this retrospective study is to describe the bacterial distribution of invasive bacterial infections in children with sickle cell disease in France between 2020 and 2025. The results may help improve knowledge of these infections and guide future prevention strategies, including antibiotic management and vaccination policies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
Shorter than P25 for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2026
CompletedFirst Posted
Study publicly available on registry
June 10, 2026
CompletedStudy Start
First participant enrolled
July 15, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2027
Study Completion
Last participant's last visit for all outcomes
July 15, 2027
June 10, 2026
June 1, 2026
1 year
June 5, 2026
June 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To establish the bacterial distribution of invasive infections in children with sickle cell disease in France (bacteremia, meningitis, osteoarticular or pleural infections) between 2020 and 2025
Proportion of the different bacteria involved in IBIs in children with sickle cell disease
During the invasive bacterial infection episode occurring between January 1, 2020 and December 31, 2025
Secondary Outcomes (4)
To establish correlations between the identified bacteria and the children's clinical characteristics
During the invasive bacterial infection episode occurring between January 1, 2020 and December 31, 2025
To assess the theoretical coverage of PCV13, PCV15 and PCV20 vaccines against the serotypes of S. pneumoniae strains responsible for invasive infections
During the invasive bacterial infection episode occurring between January 1, 2020 and December 31, 2025
To calculate the incidence of IBIs in febrile children with sickle cell disease in the subgroup of centres able to provide the number of patient-years over this period
From January 1, 2020 to December 31, 2025
To estimate the incidence of IBIs in children with sickle cell disease in France
From January 1, 2020 to December 31, 2025
Eligibility Criteria
Children with sickle cell disease followed in participating French hospital centers
You may qualify if:
- Children with sickle cell disease aged under 18 years
- Hospitalized between January 2020 and December 2025
- Hospitalized for an invasive bacterial infection clinically defined as meningitis, pleuropneumonia, osteoarticular infection, or primary bacteremia
- Bacterium identified by culture or PCR
You may not qualify if:
- Opposition from the child or his/her parents
- Bacterium identified by serology
- Urinary tract infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (31)
Hôpital Victor Dupouy (CH Argenteuil)
Argenteuil, France
CHI Robert Ballanger
Aulnay-sous-Bois, France
Hôpital Jean Verdier
Bondy, France
Hôpital Pellegrin - Hôpital des Enfants
Bordeaux, France
Hôpital Ambroise Paré
Boulogne-Billancourt, France
Hôpital Saint Camille
Bry-sur-Marne, France
Hôpital NOVO
Cergy-Pontoise, France
Hôpital Antoine Béclère
Clamart, France
CH Sud Francilien
Corbeil-Essonnes, France
CHI Créteil
Créteil, France
CH du Sud Seine et Marne
Fontainebleau, France
CH Gonesse
Gonesse, France
GHEF, Site de Marne-la-Vallée
Jossigny, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
GHT Yvelines Nord
Mantes-la-Jolie, France
Hôpital Nord, AP-HM
Marseille, France
GHEF, Site de Meaux
Meaux, France
GH Sud Ile-de-france
Melun, France
GHI Le Raincy-Montfermeil
Montfermeil, France
CHU Nantes
Nantes, France
CH Rives de Seine, Site de Neuilly-sur-Seine
Neuilly-sur-Seine, France
CHU Lenval
Nice, France
Hôpital Paris-Saclay
Orsay, France
Hôpital Necker
Paris, France
Hôpital Robert Debré
Paris, France
Hôpital Trousseau
Paris, France
CHI Poissy
Poissy, France
CH Rambouillet
Rambouillet, France
CH Saint Denis, Hôpital Delafontaine
Saint-Denis, France
Hôpital André Mignot
Versailles, France
Hôpital Intercommunal Villeneuve-St-Georges
Villeneuve-Saint-Georges, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2026
First Posted
June 10, 2026
Study Start (Estimated)
July 15, 2026
Primary Completion (Estimated)
July 15, 2027
Study Completion (Estimated)
July 15, 2027
Last Updated
June 10, 2026
Record last verified: 2026-06